XNYS
ZTS
Market cap31bUSD
Jul 09, Last price
75.08USD
1D
-0.03%
1Q
-36.30%
Jan 2017
40.26%
IPO
142.04%
Name
Zoetis Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zoetis Inc. is a global enterprise dedicated to the research, development, production, and marketing of a broad spectrum of animal health products. Operating both within the United States and globally, the company primarily serves a diverse range of animals, including major livestock categories such as cattle, swine, poultry, fish, and sheep, alongside companion animals like dogs, cats, and horses. Their extensive portfolio features various solutions, including biological vaccines engineered to prevent ailments of the respiratory, gastrointestinal, and reproductive systems, or to stimulate targeted immune responses. They also provide anti-infectives designed to combat bacterial, fungal, or protozoal pathogens, and parasiticides effective against both internal (e.g., worms) and external (e.g., fleas, ticks) parasites. Beyond these, Zoetis offers a suite of other pharmaceutical products, spanning pain management, sedation, antiemetics, reproductive aids, and oncology treatments. Their offerings also include dermatological solutions for allergic skin conditions and atopic dermatitis, as well as medicated feed additives specifically for livestock. The company further innovates in diagnostic tools, offering portable blood and urine analysis systems, point-of-care devices, instruments, reagents, rapid immunoassay tests, reference laboratory services, and blood glucose monitors. Non-pharmaceutical lines extend to nutritional supplements, agribusiness support, biodevices, genetic testing, and precision animal health technologies. Zoetis reaches its customer base, which comprises veterinarians, livestock producers, and retail outlets, through its own sales representatives and specialized technical and veterinary operations personnel, as well as via third-party veterinary distributors. Founded in 1952, the firm maintains its headquarters in Parsippany, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||